George Simeon
Insider CIK 1595117 · GNCA Director · PRNB Director, 10% owner · AVLN 10% owner · TPTX Director · CRSP Director · ACLX 10% owner · NKTX Director · ADRX Director, 10% owner · DSGN Director, 10% owner · EFTR 10% owner · ODTX 10% owner · ZBIO 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | M Exercise deriv | 2026-10-14 | 2026-10-16 | 30,000 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | S Sale | 2026-10-14 | 2026-10-16 | 14,514 | $49.63 | $720.4K | 15,486 | SEC↗ |
| CRSP CRISPR Therapeutics AG | M Exercise | 2026-10-14 | 2026-10-16 | 30,000 | $14.00 | $420.0K | 30,000 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 198,019 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 3,907,547 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 1,802,885 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 600,962 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 1,304,883 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 1,953,773 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 3,334,938 | — | $0 | 3,334,938 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 1,113,666 | — | $0 | 4,448,604 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 512,897 | — | $0 | 4,961,501 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-29 | 592,593 | $17.00 | $10.07M | 5,554,094 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 1,538,691 | — | $0 | 1,538,691 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-29 | 414,814 | $17.00 | $7.05M | 1,953,505 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 1,667,468 | — | $0 | 1,667,468 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 169,001 | — | $0 | 1,836,469 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-29 | 592,593 | $17.00 | $10.07M | 592,593 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 198,019 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 1,953,773 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 1,802,885 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 600,962 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 1,304,883 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion deriv | 2026-09-28 | 2026-09-29 | 3,907,547 | — | $0 | 0 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-29 | 592,593 | $17.00 | $10.07M | 592,593 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 169,001 | — | — | 1,836,469 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 1,667,468 | — | — | 1,667,468 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-29 | 414,814 | $17.00 | $7.05M | 1,953,505 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 1,538,691 | — | — | 1,538,691 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | P Buy | 2026-09-28 | 2026-09-29 | 592,593 | $17.00 | $10.07M | 5,554,094 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 512,897 | — | — | 4,961,501 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 1,113,666 | — | — | 4,448,604 | SEC↗ |
| ADRX ADARx Pharmaceuticals, Inc | C Conversion | 2026-09-28 | 2026-09-29 | 3,334,938 | — | — | 3,334,938 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2026-06-10 | 2026-06-11 | 37,000 | — | $0 | 37,000 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2026-06-05 | 2026-06-09 | 13,000 | — | $0 | 13,000 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 2,374,981 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 4,606,320 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 1,299,842 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 544,162 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 600,142 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 6,644,650 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | X Exercise deriv | 2026-05-11 | 2026-05-11 | 764,312 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 2,657,860 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 4,500,000 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | X Exercise deriv | 2026-05-11 | 2026-05-11 | 484,395 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 1,614,650 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 200,000 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 1,899,984 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | X Exercise deriv | 2026-05-11 | 2026-05-11 | 1,861,211 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion deriv | 2026-05-11 | 2026-05-11 | 1,151,580 | — | $0 | 0 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 139,366 | — | $0 | 613,414 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | S Sale | 2026-05-11 | 2026-05-11 | 438 | $18.00 | $7.9K | 814,851 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | X Exercise | 2026-05-11 | 2026-05-11 | 78,656 | — | $0 | 815,289 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 273,527 | — | $0 | 736,633 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 463,106 | — | $0 | 463,106 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | P Buy | 2026-05-11 | 2026-05-11 | 133,333 | $18.00 | $2.40M | 574,314 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | S Sale | 2026-05-11 | 2026-05-11 | 277 | $18.00 | $5.0K | 440,981 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | X Exercise | 2026-05-11 | 2026-05-11 | 49,850 | — | $0 | 441,258 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 166,168 | — | $0 | 391,408 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 20,582 | — | $0 | 225,240 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 204,658 | — | $0 | 204,658 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 255,823 | — | $0 | 374,335 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 118,512 | — | $0 | 118,512 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | P Buy | 2026-05-11 | 2026-05-11 | 222,222 | $18.00 | $4.00M | 1,831,383 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | S Sale | 2026-05-11 | 2026-05-11 | 1,065 | $18.00 | $19.2K | 1,609,161 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | X Exercise | 2026-05-11 | 2026-05-11 | 191,541 | — | $0 | 1,610,226 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 683,817 | — | $0 | 1,418,685 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 61,762 | — | $0 | 734,868 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 59,692 | — | $0 | 673,106 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | P Buy | 2026-05-11 | 2026-05-11 | 200,000 | $18.00 | $3.60M | 1,014,851 | SEC↗ |
| ODTX Odyssey Therapeutics, Inc. | C Conversion | 2026-05-11 | 2026-05-11 | 474,048 | — | $0 | 474,048 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-01 | 27,309,719 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-01 | 9,418,560 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-01 | 9,418,561 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion deriv | 2026-05-01 | 2026-05-01 | 6,827,429 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion | 2026-05-01 | 2026-05-01 | 489,486 | — | $0 | 844,310 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion | 2026-05-01 | 2026-05-01 | 1,419,298 | — | $0 | 1,419,298 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion | 2026-05-01 | 2026-05-01 | 489,486 | — | $0 | 1,908,784 | SEC↗ |
| AVLN Avalyn Pharma Inc. | P Buy | 2026-05-01 | 2026-05-01 | 277,778 | $18.00 | $5.00M | 2,186,562 | SEC↗ |
| AVLN Avalyn Pharma Inc. | C Conversion | 2026-05-01 | 2026-05-01 | 354,824 | — | $0 | 354,824 | SEC↗ |
| AVLN Avalyn Pharma Inc. | P Buy | 2026-05-01 | 2026-05-01 | 277,777 | $18.00 | $5.00M | 1,122,087 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2025-10-09 | 2025-10-14 | 63,158 | $19.00 | $1.20M | 1,173,395 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2025-10-09 | 2025-10-14 | 63,157 | $19.00 | $1.20M | 1,917,895 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2025-07-16 | 2025-07-17 | 6,510 | $52.03 | $338.7K | 69,687 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2025-07-16 | 2025-07-17 | 960,983 | $52.03 | $50.00M | 1,730,179 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2025-07-16 | 2025-07-17 | 22,319 | $52.03 | $1.16M | 238,897 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2025-06-10 | 2025-06-12 | 19,000 | — | $0 | 19,000 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2025-06-05 | 2025-06-06 | 13,000 | — | $0 | 13,000 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2025-06-05 | 2025-06-09 | 46,000 | — | $0 | 46,000 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 13,071,439 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 4,357,146 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 5,809,528 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2024-09-16 | 2024-09-16 | 441,176 | $17.00 | $7.50M | 1,946,564 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2024-09-16 | 2024-09-16 | 1,352,942 | $17.00 | $23.00M | 1,854,738 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 1,505,388 | — | $0 | 1,505,388 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2024-09-16 | 2024-09-16 | 441,176 | $17.00 | $7.50M | 1,110,237 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 669,061 | — | $0 | 669,061 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 501,796 | — | $0 | 501,796 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2024-06-13 | 2024-06-14 | 22,500 | — | $0 | 22,500 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2024-06-13 | 2024-06-17 | 19,000 | — | $0 | 19,000 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2024-05-30 | 2024-05-31 | 13,000 | — | $0 | 13,000 | SEC↗ |
| NKTX Nkarta, Inc. | P Buy | 2024-03-27 | 2024-03-28 | 451,659 | $10.00 | $4.52M | 451,659 | SEC↗ |
| NKTX Nkarta, Inc. | P Buy | 2024-03-27 | 2024-03-28 | 1,548,341 | $10.00 | $15.48M | 1,548,341 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award | 2024-02-27 | 2024-02-27 | 63,177 | $71.50 | $4.52M | 63,177 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award | 2024-02-27 | 2024-02-27 | 769,196 | $71.50 | $55.00M | 769,196 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award | 2024-02-27 | 2024-02-27 | 216,578 | $71.50 | $15.49M | 216,578 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | S Sale | 2023-11-27 | 2023-11-29 | 178,585 | $0.61 | $108.9K | 1,821,415 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | S Sale | 2023-11-27 | 2023-11-29 | 430,578 | $0.61 | $262.7K | 4,391,536 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2023-06-08 | 2023-06-09 | 13,000 | — | $0 | 13,000 | SEC↗ |
| NKTK Nkarta, Inc. | A Award deriv | 2023-06-07 | 2023-06-09 | 22,500 | — | $0 | 22,500 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2023-05-31 | 2023-06-02 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2023-05-11 | 2023-05-15 | 631,932 | $45.00 | $28.44M | 2,834,879 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2023-05-11 | 2023-05-15 | 6,485 | $46.15 | $299.3K | 2,828,394 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2023-05-11 | 2023-05-15 | 3,804 | $46.15 | $175.6K | 1,658,780 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2023-05-11 | 2023-05-15 | 370,612 | $45.00 | $16.68M | 1,662,584 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2022-12-20 | 2022-12-20 | 40,000 | $8.14 | $325.6K | 6,526,476 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2022-12-19 | 2022-12-20 | 360,000 | $8.63 | $3.11M | 6,486,476 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2022-12-16 | 2022-12-20 | 500,000 | $8.28 | $4.14M | 6,126,476 | SEC↗ |
| TPTX Turning Point Therapeutics | D To issuer deriv | 2022-08-17 | 2022-08-17 | 8,500 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | D To issuer deriv | 2022-08-17 | 2022-08-17 | 8,500 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | D To issuer deriv | 2022-08-17 | 2022-08-17 | 15,000 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | D To issuer | 2022-08-17 | 2022-08-17 | 2,253,660 | $76.00 | $171.28M | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2022-06-15 | 2022-06-16 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2022-06-09 | 2022-06-10 | 12,000 | — | $0 | 12,000 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2022-06-08 | 2022-06-10 | 16,000 | — | $0 | 16,000 | SEC↗ |
| NKTX Nkarta, Inc. | P Buy | 2022-04-28 | 2022-04-29 | 666,667 | $15.00 | $10.00M | 666,667 | SEC↗ |
| NKTX Nkarta, Inc. | P Buy | 2022-04-28 | 2022-04-29 | 666,666 | $15.00 | $10.00M | 666,666 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 649,795 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 533,389 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 433,196 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 1,550,309 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 666,651 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 666,651 | — | $0 | 2,216,960 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 433,196 | — | $0 | 433,196 | SEC↗ |
| ACLX Arcellx, Inc. | P Buy | 2022-02-08 | 2022-02-10 | 66,667 | $15.00 | $1.00M | 3,466,811 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 649,795 | — | $0 | 3,400,144 | SEC↗ |
| ACLX Arcellx, Inc. | P Buy | 2022-02-08 | 2022-02-10 | 1,600,000 | $15.00 | $24.00M | 2,033,196 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 1,550,309 | — | $0 | 1,550,309 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 533,389 | — | $0 | 2,750,349 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2021-06-13 | 2021-06-15 | 16,511 | — | $0 | 16,511 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2021-06-10 | 2021-06-14 | 10,000 | — | $0 | 10,000 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2021-06-02 | 2021-06-04 | 8,500 | — | $0 | 8,500 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 1,526,718 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 7,236,938 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion | 2021-03-30 | 2021-04-01 | 936,637 | — | $0 | 5,376,476 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2021-03-30 | 2021-04-01 | 250,000 | $20.00 | $5.00M | 5,626,476 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion | 2021-03-30 | 2021-04-01 | 4,439,839 | — | $0 | 4,439,839 | SEC↗ |
| DSGN Design Therapeutics, Inc. | A Award deriv | 2021-03-25 | 2021-03-29 | 15,000 | — | $0 | 15,000 | SEC↗ |
| PRNB Principia Biopharma Inc. | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | D To issuer deriv | 2020-09-28 | 2020-09-28 | 20,475 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | D To issuer deriv | 2020-09-28 | 2020-09-28 | 28,623 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | U Tender | 2020-09-28 | 2020-09-28 | 2,982,855 | $100.00 | $298.29M | 0 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2020-07-09 | 2020-07-13 | 10,700 | — | $0 | 10,700 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2020-06-15 | 2020-06-17 | 8,500 | — | $0 | 8,500 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2020-06-11 | 2020-06-15 | 15,000 | — | $0 | 15,000 | SEC↗ |
| PRNB Principia Biopharma Inc. | A Award deriv | 2020-06-04 | 2020-06-08 | 10,240 | — | $0 | 10,240 | SEC↗ |
| TPTX Turning Point Therapeutics | P Buy | 2020-05-21 | 2020-05-26 | 83,333 | $60.00 | $5.00M | 2,253,660 | SEC↗ |
| PRNB Principia Biopharma Inc. | P Buy | 2019-10-18 | 2019-10-22 | 357,142 | $28.00 | $10.00M | 2,982,855 | SEC↗ |
| TPTX Turning Point Therapeutics | P Buy | 2019-09-10 | 2019-09-11 | 177,777 | $45.00 | $8.00M | 2,170,327 | SEC↗ |
| PRNB Principia Biopharma Inc. | A Award deriv | 2019-06-11 | 2019-06-11 | 10,240 | — | $0 | 10,240 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2019-06-11 | 2019-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2019-04-22 | 2019-04-24 | 15,000 | — | $0 | 15,000 | SEC↗ |
| TPTX Turning Point Therapeutics | C Conversion deriv | 2019-04-22 | 2019-04-24 | 2,105,259 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | C Conversion deriv | 2019-04-22 | 2019-04-24 | 4,314,809 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | C Conversion | 2019-04-22 | 2019-04-24 | 546,820 | — | $0 | 1,667,550 | SEC↗ |
| TPTX Turning Point Therapeutics | C Conversion | 2019-04-22 | 2019-04-24 | 1,120,730 | — | $0 | 1,120,730 | SEC↗ |
| TPTX Turning Point Therapeutics | P Buy | 2019-04-22 | 2019-04-24 | 325,000 | $18.00 | $5.85M | 1,992,550 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | P Buy | 2018-09-18 | 2018-09-20 | 270,000 | $17.00 | $4.59M | 2,625,713 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 1,070,771 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 1,383,512 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 1,644,129 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 2,188,176 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 2,355,713 | SEC↗ |
| PRNB Principia Biopharma Inc. | A Award deriv | 2018-09-13 | 2019-01-10 | 20,475 | — | $0 | 20,475 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2018-06-15 | 2018-06-19 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2017-05-31 | 2017-06-02 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-10-26 | 2,942,560 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-10-26 | 211,567 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-10-26 | 211,567 | — | $0 | 3,154,127 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2016-10-24 | 2016-10-26 | 66,500 | $14.00 | $931.0K | 3,220,627 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-10-26 | 2,942,560 | — | $0 | 2,942,560 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2016-10-18 | 2016-10-20 | 30,000 | — | $0 | 30,000 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion deriv | 2014-02-10 | 2014-02-11 | 4,099,231 | — | $0 | 0 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion deriv | 2014-02-10 | 2014-02-11 | 4,851,958 | — | $0 | 0 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion deriv | 2014-02-10 | 2014-02-11 | 9,230,769 | — | $0 | 0 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion | 2014-02-10 | 2014-02-11 | 407,727 | — | $0 | 1,671,667 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion | 2014-02-10 | 2014-02-11 | 344,473 | — | $0 | 1,263,940 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion | 2014-02-10 | 2014-02-11 | 775,694 | — | $0 | 919,467 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | P Buy | 2014-02-10 | 2014-02-11 | 143,773 | $12.00 | $1.73M | 143,773 | SEC↗ |